SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and developer of molecular diagnostic products, today announced that it has received market approval from the Australian Therapeutic Goods Administration (TGA), clearing the company to market its Prosigna™ Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s risk of distant recurrence of disease. The Prosigna Assay was launched in the U.S. in December 2013 and is also CE Marked for in vitro diagnostic use in the European Union and Israel, and is licensed for use in Canada.
Help employers find you! Check out all the jobs and post your resume.
